Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/immunology/mortality/pathology/*therapy Chemotherapy Adjuvant/methods/statistics & numerical data Clinical Trials Phase I as Topic Clinical Trials Phase II as Topic Cystectomy Disease-Free Survival Follow-Up Studies Humans Immune Checkpoint Inhibitors/*therapeutic use Muscle Smooth/pathology/surgery Neoadjuvant Therapy/*methods/statistics & numerical data Neoplasm Invasiveness/pathology Prospective Studies Treatment Outcome Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/immunology/mortality/pathology/*therapy Bladder cancer Immune checkpoint inhibitors Immunotherapy Neoadjuvant

*Cystectomy/methods Humans *Nutritional Status Postoperative Complications/*epidemiology/mortality Preoperative Period Urinary Bladder Neoplasms/*surgery Bladder cancer Complications Cystectomy Mortality Nutritional status Sarcopenia

Antineoplastic Agents Alkylating/pharmacology/*therapeutic use Cyclophosphamide/pharmacology/*therapeutic use Female Humans Male Survival Analysis Urinary Bladder Neoplasms/*drug therapy/mortality Cyclophosphamide Hematuria Systematic review Urinary bladder neoplasms

Adult Aged Aged 80 and over B7-H1 Antigen/genetics/*immunology Female Humans Immune Checkpoint Inhibitors/*administration & dosage *Immunotherapy Male Middle Aged Programmed Cell Death 1 Receptor/genetics/*immunology Progression-Free Survival Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy efficacy immunotherapy meta-analysis safety urothelial cancer this study.

Carcinoma Transitional Cell/*mortality/pathology/surgery Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Risk Assessment/methods Urinary Bladder/*pathology/surgery Urinary Bladder Neoplasms/*mortality/pathology/surgery Urothelium/*pathology/surgery histology meta-analysis urinary bladder neoplasms

Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Smoking/*adverse effects Survival Rate Treatment Outcome Urinary Bladder Neoplasms/drug therapy/*mortality/*surgery cigarette smoking cystectomy recurrence survival urinary bladder neoplasms

*Biomarkers Tumor Carcinoma Transitional Cell/*genetics/mortality/pathology *DNA Methylation Humans Neoplasm Invasiveness Prognosis Risk Assessment Survival Rate Urinary Bladder Neoplasms/*genetics/mortality/pathology Biomarkers Dna High-risk non–muscle-invasive bladder cancer Methylation Prognostic markers Systematic review molecular markers

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Neoplasm Invasiveness Survival Rate Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/*surgery Muscle-invasive bladder cancer Neoadjuvant chemotherapy Overall survival Radical cystectomy

*Cystectomy/methods Humans Postoperative Complications/*epidemiology Prognosis Survival Rate Urinary Bladder Neoplasms/*mortality/*surgery Bladder cancer clinical markers morbidity mortality radical cystectomy survival

Adult Aged Aged 80 and over Cystectomy/methods/mortality Female Humans Hydronephrosis/*physiopathology/surgery Male Middle Aged Neoplasm Staging Prognosis Proportional Hazards Models Retrospective Studies Urinary Bladder/pathology Urinary Bladder Neoplasms/*complications/*pathology

Carcinoma Papillary/mortality/pathology/*therapy Disease Progression Humans Neoplasm Staging Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Urothelium/*pathology Bacillus Calmette-Guérin therapy Bladder cancer Bladder sparing Immediate cystectomy Micropapillary Prognosis Transurethral resection Urothelial carcinoma Variant histology

Blood Loss Surgical/statistics & numerical data Blood Transfusion/statistics & numerical data Cystectomy/*adverse effects/methods Hospital Mortality Humans Length of Stay/statistics & numerical data Operative Time Postoperative Complications/*epidemiology/etiology Quality of Life Risk Factors Robotic Surgical Procedures/*adverse effects Treatment Outcome Urinary Bladder/surgery Urinary Bladder Neoplasms/*surgery Urinary Diversion/*adverse effects/methods health-related quality of life meta-analysis open radical cystectomy postoperative complication robot-assisted radical cystectomy

B7-H1 Antigen/*metabolism Biomarkers Tumor/metabolism Carcinoma Transitional Cell/metabolism/*mortality/pathology Cell Membrane/metabolism Gene Expression Regulation Neoplastic Humans Neoplasm Staging Prognosis Survival Analysis *Up-Regulation Urinary Bladder Neoplasms/metabolism/*mortality/pathology Biomarker Meta-analysis Pd-l1 Urothelial carcinoma

Cystectomy/methods/*mortality Humans Lymph Node Excision/methods/*mortality Lymph Nodes/surgery Lymphatic Metastasis Pelvis/pathology Postoperative Complications/etiology Prognosis Randomized Controlled Trials as Topic Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/pathology/*surgery

Carcinoma in Situ/diagnosis/epidemiology/*pathology/surgery *Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Survival Analysis Treatment Outcome Ureteral Neoplasms/*diagnosis/epidemiology/pathology/secondary Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/*pathology/surgery

Databases Factual Disease-Free Survival Humans Lymphocytes/*cytology/immunology Neoplasm Metastasis Neutrophils/*cytology/immunology Odds Ratio Prognosis Proportional Hazards Models Risk Assessment Survival Rate Urinary Bladder Neoplasms/immunology/mortality/*pathology Urologic Neoplasms/immunology/mortality/*pathology Bladder cancer Metastatic unresectable urothelial carcinoma Neutrophil-Lymphocyte ratio Unresectable urothelial carcinoma

Carcinogens Environmental/adverse effects Gene-Environment Interaction Humans Incidence Occupational Exposure/adverse effects Prevalence Risk Assessment Risk Factors Smoking/adverse effects/epidemiology Time Factors Urinary Bladder Neoplasms/diagnosis/*epidemiology/genetics/mortality Bladder Cancer Epidemiology Urothelial

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Aged Diabetes Mellitus Type 2/complications/*drug therapy Disease Progression Disease-Free Survival Female Humans Hypoglycemic Agents/*therapeutic use Male Metformin/*therapeutic use Middle Aged Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Urinary Bladder Neoplasms/etiology/*mortality

Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy